These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Management of cytomegalovirus infection after solid-organ or stem-cell transplantation. Current guidelines and future prospects. Hebart H; Kanz L; Jahn G; Einsele H Drugs; 1998 Jan; 55(1):59-72. PubMed ID: 9463790 [TBL] [Abstract][Full Text] [Related]
11. Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation. Maffini E; Giaccone L; Festuccia M; Brunello L; Busca A; Bruno B Expert Rev Hematol; 2016 Jun; 9(6):585-96. PubMed ID: 27043241 [TBL] [Abstract][Full Text] [Related]
12. Fatal cytomegalovirus pneumonia after preemptive antiviral therapy in a renal transplant recipient. Ketteler M; Preuschof L; Mertz A; Stöffler-Meilicke M; Schäfer H; Distler A; Offermann G Clin Nephrol; 2000 Nov; 54(5):418-24. PubMed ID: 11105806 [TBL] [Abstract][Full Text] [Related]
13. Current antiviral strategies for controlling cytomegalovirus in hematopoietic stem cell transplant recipients: prevention and therapy. Boeckh M Transpl Infect Dis; 1999 Sep; 1(3):165-78. PubMed ID: 11428987 [TBL] [Abstract][Full Text] [Related]
14. Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Noble S; Faulds D Drugs; 1998 Jul; 56(1):115-46. PubMed ID: 9664203 [TBL] [Abstract][Full Text] [Related]
15. Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients. Torres-Madriz G; Boucher HW Clin Infect Dis; 2008 Sep; 47(5):702-11. PubMed ID: 18652557 [TBL] [Abstract][Full Text] [Related]
16. Case report: persistent cytomegalovirus (CMV) infection after haploidentical hematopoietic stem cell transplantation using in vivo alemtuzumab: emergence of resistant CMV due to mutations in the UL97 and UL54 genes. Oshima K; Kanda Y; Kako S; Asano-Mori Y; Watanabe T; Motokura T; Chiba S; Shiraki K; Kurokawa M J Med Virol; 2008 Oct; 80(10):1769-75. PubMed ID: 18712833 [TBL] [Abstract][Full Text] [Related]
17. New Developments in the Management of Cytomegalovirus Infection After Transplantation. Meesing A; Razonable RR Drugs; 2018 Jul; 78(11):1085-1103. PubMed ID: 29961185 [TBL] [Abstract][Full Text] [Related]
18. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Boeckh M; Nichols WG Blood; 2004 Mar; 103(6):2003-8. PubMed ID: 14644993 [TBL] [Abstract][Full Text] [Related]
19. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Flechner SM; Avery RK; Fisher R; Mastroianni BA; Papajcik DA; O'Malley KJ; Goormastic M; Goldfarb DA; Modlin CS; Novick AC Transplantation; 1998 Dec; 66(12):1682-8. PubMed ID: 9884259 [TBL] [Abstract][Full Text] [Related]
20. Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation. Battiwalla M; Paplham P; Almyroudis NG; McCarthy A; Abdelhalim A; Elefante A; Smith P; Becker J; McCarthy PL; Segal BH Transpl Infect Dis; 2007 Mar; 9(1):28-32. PubMed ID: 17313468 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]